Thrombolysis is a medical treatment that uses clot-dissolving drugs to break up dangerous blood clots inside your blood vessels. It’s most commonly used as an emergency treatment for ischemic stroke, heart attack, and severe pulmonary embolism, where restoring blood flow quickly can mean the difference between recovery and permanent damage. The treatment works within a narrow time window, making speed critical.
How Thrombolysis Dissolves Clots
Your body already has a built-in system for dissolving clots called fibrinolysis. Thrombolytic drugs supercharge this natural process. They work by activating a protein in your blood called plasminogen, converting it into its active form, plasmin. Plasmin then attacks fibrin, the mesh-like protein that holds a blood clot together, breaking it apart so blood can flow freely again.
The drugs used in thrombolysis are called plasminogen activators, and they’re modeled after a substance your body produces naturally. The most widely used versions include alteplase, tenecteplase, and reteplase. Newer-generation drugs like tenecteplase offer practical advantages: they can be given as a single injection rather than a 60-minute infusion, and they stay active in the bloodstream longer. American Heart Association guidelines now endorse tenecteplase as an equal alternative to alteplase for stroke treatment.
Conditions Treated With Thrombolysis
Thrombolysis is reserved for situations where a blood clot is causing serious, time-sensitive damage to an organ. The three most common scenarios are:
- Ischemic stroke: A clot blocks blood flow to the brain. Thrombolysis is the standard of care when given within 4.5 hours of symptom onset.
- Heart attack (STEMI): A clot blocks a coronary artery. Thrombolytics are used for a specific type of heart attack identified by characteristic changes on an ECG, particularly when a catheterization lab isn’t available quickly enough.
- Pulmonary embolism: A clot lodges in the lungs. In patients with intermediate-risk pulmonary embolism and signs of heart strain, thrombolysis has been associated with roughly half the mortality rate compared to blood thinners alone.
The Time Window Matters
For ischemic stroke, the treatment window is 4.5 hours from when symptoms first appeared or when the patient was last known to be well. This is a hard deadline. Brain tissue dies rapidly without blood flow, and every minute of delay reduces the likelihood of a good outcome. The phrase “time is brain” exists for this reason.
For heart attacks, the window is generally up to 12 hours, though earlier treatment produces better results. In pulmonary embolism, timing depends more on how unstable the patient is than on a fixed clock, but the same principle applies: faster treatment preserves more heart and lung function.
Two Ways Thrombolysis Is Delivered
The most common method is systemic thrombolysis, where the drug is injected into a vein in your arm and travels through your entire bloodstream to reach the clot. For stroke, this typically means a dose calculated by body weight, with a small initial portion given quickly and the rest infused over about an hour.
The second approach is catheter-directed thrombolysis, where doctors thread a thin tube through your blood vessels and deliver the drug directly to the clot. This allows a lower dose of the drug because it’s concentrated right where it’s needed, which can reduce bleeding complications. Catheter-directed approaches have become particularly important for pulmonary embolism, where newer techniques combine drug delivery with ultrasound waves to help break up the clot more effectively.
Risks and Bleeding Complications
The most serious risk of thrombolysis is bleeding, because the same mechanism that dissolves a harmful clot can also interfere with beneficial clotting elsewhere in the body. The most dangerous form is bleeding inside the brain. In stroke patients treated with thrombolytics, symptomatic brain hemorrhage occurs in roughly 2% to 7% of cases, depending on how it’s measured and how quickly treatment was given. Real-world registries tend to report lower rates (around 3.5%) than clinical trials (around 7.4%), likely because clinical practice has improved over time.
For pulmonary embolism, a large meta-analysis published in JAMA found that thrombolysis roughly tripled the rate of major bleeding compared to blood thinners alone. This is why the decision to use thrombolytics always involves weighing the severity of the clot against the bleeding risk. In life-threatening situations, the benefit usually outweighs the danger.
Who Cannot Receive Thrombolysis
Several conditions make thrombolysis too dangerous. The most important absolute contraindications include:
- Active bleeding in the brain: Any sign of hemorrhage on a brain scan rules out thrombolysis entirely.
- History of brain hemorrhage: Even a past episode increases risk enough to disqualify most patients.
- Recent head trauma or stroke: Significant head injury or a prior stroke within the past three months.
- Low platelet count or bleeding disorders: If your blood doesn’t clot properly on its own, adding a clot-dissolving drug is too risky.
- Current use of blood thinners: Patients already on anticoagulants with elevated clotting times face higher bleeding risk.
- Brain tumors, aneurysms, or abnormal blood vessel formations: These structural issues make brain bleeding far more likely.
Recent major surgery and recent gastrointestinal bleeding are also considered contraindications, though doctors sometimes weigh these on a case-by-case basis when the clot itself is immediately life-threatening.
What Happens After Treatment
After receiving thrombolytics, you’ll be monitored closely in an intensive care or stroke unit. Blood pressure control is a major focus. Guidelines call for keeping blood pressure below 180/105 in the first 24 hours after treatment for stroke patients, and some research suggests that bringing it even lower, below 140 systolic, is associated with better 90-day outcomes. Frequent neurological checks assess whether the treatment is working or whether complications are developing.
You won’t receive blood thinners or antiplatelet drugs for at least 24 hours after thrombolysis, because the bleeding risk remains elevated during that period. A follow-up brain scan is typically done before any additional blood-thinning medication is started.
Thrombolysis vs. Mechanical Thrombectomy
For large-vessel strokes, where a major artery feeding the brain is blocked, thrombolytic drugs alone often aren’t enough. Intravenous thrombolysis successfully reopens less than 10% of blockages in the largest brain arteries. In these cases, mechanical thrombectomy, a procedure where doctors physically remove the clot using a catheter device, produces far better results.
The two treatments aren’t always an either-or choice. Many stroke patients receive thrombolytics first to start dissolving the clot immediately, then undergo thrombectomy to remove whatever remains. Thrombectomy requires specialized neurovascular teams and equipment that aren’t available at every hospital, which is one reason thrombolysis remains the frontline treatment: it can be started at any emergency department with a CT scanner and the right medication on hand.